Inozyme Pharma, Inc.

NasdaqGS INZY

Inozyme Pharma, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 49.09

Inozyme Pharma, Inc. Price to Sales Ratio (P/S) is 49.09 on January 14, 2025, a -62.64% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Inozyme Pharma, Inc. 52-week high Price to Sales Ratio (P/S) is 243.11 on March 28, 2024, which is 395.22% above the current Price to Sales Ratio (P/S).
Inozyme Pharma, Inc. 52-week low Price to Sales Ratio (P/S) is 49.09 on January 14, 2025, which is 0.00% below the current Price to Sales Ratio (P/S).
Inozyme Pharma, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 151.97.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: INZY

Inozyme Pharma, Inc.

CEO	Dr. Douglas A. Treco Ph.D.
IPO Date	July 24, 2020
Location	United States
Headquarters	321 Summer Street
Employees	59
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key trends

Past 5 years